Conceptio › Archive › ClinicalTrials.gov
ClinicalTrials.govpublic full text

Icaritin Soft Capsule Versus Huachansu Tablet in the First-line Treatment of Unresectable Hepatocellular Carcinoma With Poor Conditions and Biomarker Enrichment (Biomarker Enrichment Study of Poor Prognosis HCC Patients, BESTPOP)

Beijing Shenogen Biomedical Co., Ltd · 2022
ClinicalTrials.gov · Datasets · License: Public Domain · 2022
Open Source ↗
firsthepatocellularcarcinoma
hepatocellular carcinoma, icaritin, poor conditions, composite biomarker, first-line treatment, interventional, phase3
This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Related documents

Record · ID 895521
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.